Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder



Status:Completed
Conditions:Anxiety, Psychiatric
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:18 - 65
Updated:4/21/2016
Start Date:July 2007
End Date:March 2008

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Multicenter, Randomized, Double-Blind, Placebo and Escitalopram Controlled Trial of the Safety and Efficacy of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder

The purpose of this study is to learn about the safety and efficacy of pexacerfont in
outpatients diagnosed with Generalized Anxiety Disorder


Inclusion Criteria:

- Outpatient women ages 18-65 meeting Diagnostic and Statistical Manual of Mental
Disorders Manual, Fourth Edition, Text Revision (DSM-IV TR) criteria for Generalized
Anxiety Disorder (GAD), either moderate or severe (300.02)

Exclusion Criteria:

- Males

- Patients who report a history of inadequate response to three or more adequate trials
of any selective Serotonin reuptake inhibitors (SSRIs) for GAD within the last three
years
We found this trial at
0
sites